---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269573"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:47:12.602689+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tectonic Q3 net loss $19M; positive TX45 Phase 1b data in PH-HFrEF

## Summary
- Net loss of $19.0M in Q3 2025 vs $17.7M in Q3 2024; R&D expenses $16.9M.
- Cash and equivalents $268.4M as of Sept 30, 2025; runway into Q4 2028.
- TX45 Part B: 29.2% reduction in PCWP, 17.3% improvement in cardiac output in PH-HFrEF.
- TX45 APEX Phase 2 in PH-HFpEF over 50% enrolled; topline results expected in 2026.
- TX2100 Phase 1 for HHT to start Q1 2026; TX45 PH-ILD Phase 2 planned in 2026.

## SEC filing metadata
- accession: 0001193125-25-269573
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/0001193125-25-269573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312525269573/tecx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269573
- JSON: https://secwatch.observer/filing/0001193125-25-269573.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.